TCT 2018 | ULTIMATE: IVUS Guided DES Implantation for All Vessels, for All Lesions

Intravascular Ultrasound (IVUS) guided drug eluting stent (DES) implantation is associated with less adverse events compared against angiography guided stenting. This is especially clear for certain populations (with left main PCI as paradigmatic) but not so clear when dealing with all comers.

TCT 2018 | ULTIMATE: Implante de DES guiado por IVUS, para todos los vasos, para todas las lesiones1448 all comer patients requiring DES stenting were randomized 1:1 to IVUS guided vs. angiography guided procedures.  Primary end point at 12 months was a composite of cardiac death, target vessel myocardial infarction or clinically driven target vessel revascularization. The procedure was considered successful if all IVUS optimal implantation criteria were met.

 

At 12 months, there was 2.9% events rate in the IVUS group vs 5.4% in the angiography guided group (p=0.019). These events happen in only 1.6% of patients who complied with optimal implantation criteria by IVUS. If one criterion was not met, the figure would rise to 4.4% (p=0.029).


Read also: TCT 2018 | SYNTAXES: 10 Year Follow Up is ‘Trendy’.


There was also significant reduction of target vessel revascularization and definite thrombosis.

 

IVUS was shown to reduce events in an unselected population of patients, and not only in complex PCI.

 

Original title: Intravascular Ultrasound-Guided Versus Angiography-Guided Implantation of Drug- Eluting Stent in All-Comers: The ULTIMATE trial.

Presenter: Junjie Zhang.

 

ULTIMATE-presentación

ULTIMATE-artículo-original


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...